201 related articles for article (PubMed ID: 34436898)
1. Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).
Kotian PL; Wu M; Vadlakonda S; Chintareddy V; Lu P; Juarez L; Kellogg-Yelder D; Chen X; Muppa S; Chambers-Wilson R; Davis Parker C; Williams J; Polach KJ; Zhang W; Raman K; Babu YS
J Med Chem; 2021 Sep; 64(17):12453-12468. PubMed ID: 34436898
[TBL] [Abstract][Full Text] [Related]
2. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema.
Hwang JR; Hwang G; Johri A; Craig T
Immunotherapy; 2019 Dec; 11(17):1439-1444. PubMed ID: 31635497
[TBL] [Abstract][Full Text] [Related]
3. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
Manning ME; Kashkin JM
Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
[No Abstract] [Full Text] [Related]
4. Berotralstat: First Approval.
Lee A
Drugs; 2021 Feb; 81(3):405-409. PubMed ID: 33646555
[TBL] [Abstract][Full Text] [Related]
5. A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.
Gao Y; Hwang J; Hwang G; Craig T
Drugs Today (Barc); 2022 Feb; 58(2):59-67. PubMed ID: 35188140
[TBL] [Abstract][Full Text] [Related]
6. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
7. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon.
Zhang W; Vadlakonda S; Wu M; Chintareddy V; Vogeti LN; Juarez L; Muppa S; Parker C; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
Bioorg Med Chem; 2022 Nov; 73():117035. PubMed ID: 36208543
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema.
Mathis A; Sale M; Cornpropst M; Sheridan WP; Ma SC
Clin Transl Sci; 2022 Apr; 15(4):1027-1035. PubMed ID: 35212456
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
[TBL] [Abstract][Full Text] [Related]
11. A review of berotralstat for the treatment of hereditary angioedema.
Farkas H; Balla Z
Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
Wedner HJ; Aygören-Pürsün E; Bernstein J; Craig T; Gower R; Jacobs JS; Johnston DT; Lumry WR; Zuraw BL; Best JM; Iocca HA; Murray SC; Desai B; Nagy E; Sheridan WP; Kiani-Alikhan S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2305-2314.e4. PubMed ID: 33866032
[TBL] [Abstract][Full Text] [Related]
13. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
[TBL] [Abstract][Full Text] [Related]
14. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
Powell J; Piszczatoski C; Rubido E
Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
[TBL] [Abstract][Full Text] [Related]
15. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches in hereditary angioedema.
Antoniu SA
Clin Rev Allergy Immunol; 2011 Aug; 41(1):114-22. PubMed ID: 21279474
[TBL] [Abstract][Full Text] [Related]
17. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Davie RL; Edwards HJ; Evans DM; Hodgson ST; Stocks MJ; Smith AJ; Rushbrooke LJ; Pethen SJ; Roe MB; Clark DE; McEwan PA; Hampton SL
J Med Chem; 2022 Oct; 65(20):13629-13644. PubMed ID: 36251573
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
Farkas H; Balla Z
Expert Opin Investig Drugs; 2024 Mar; 33(3):191-200. PubMed ID: 38366937
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ; Murugesan N; Li L; Rushbrooke LJ; Lee DK; De Donatis GM; Maetzel A; Yea CM; Hampton SL; Feener EP
Clin Exp Allergy; 2022 Sep; 52(9):1059-1070. PubMed ID: 35278245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
